FDA Approves Amgen And Allergan’s Kanjinti Trastuzumab Biosimilar
Amgen and Allergan’s biosimilar version of Herceptin has been approved by the US Food and Drug Administration.
You may also be interested in...
Genentech has been denied its request for a US injunction against Amgen over its at-risk launch of a trastuzumab biosimilar rival to Herceptin.
Amgen has launched its Kanjinti biosimilar version of trastuzumab in the US after a court refused Genentech’s request for an injunction. At the same time, Amgen has also introduced its Mvasi bevacizumab biosimilar. The launches represent Amgen’s first biosimilar introductions in the US.
In a change of strategy, Amgen has withdrawn its European application for biosimilar infliximab.